Wyeth Plans Methylnaltrexone Studies In New Patient Populations
This article was originally published in The Pink Sheet Daily
Executive Summary
Data from the three additional clinical studies would be used to expand labeling for the mu-opioid receptor antagonist following its approval, Progenics tells “The Pink Sheet” DAILY.
You may also be interested in...
Advisory Committee To Review GSK/Adolor’s Entereg
Firms hope to get the drug on the market before Wyeth/Progenics’ competing methylnaltrexone for treatment of postoperative ileus.
Advisory Committee To Review GSK/Adolor’s Entereg
Firms hope to get the drug on the market before Wyeth/Progenics’ competing methylnaltrexone for treatment of postoperative ileus.
Generic Coreg To Launch Immediately Following FDA Approval
Several generic drug makers received ANDA approval for generic versions of GlaxoSmithKline’s blockbuster heart failure medication.